Note for mobile users: This table is best viewed in horizontal (landscape) orientation.

Investment Theses

Core strategy and high-conviction rationales for active positions

Ticker	Company	Reason I'm Buying
VKTX	Viking Therapeutics	The Macro Momentum: Viking operates in the massive Obesity / GLP-1 TAM, providing crucial portfolio diversification away from micro-cap binary and niche gene-therapy bets. They boast a heavily de-risked oral and subcutaneous GLP-1/GIP dual agonist pipeline that rivals Eli Lilly and Novo Nordisk. The Near-Term Catalyst (Q3 2026): The immediate price driver is Phase 1 maintenance data reading out in Q3. The trial tests if patients can maintain weight loss after a 19-week subcutaneous run by transitioning to a weekly or daily oral pill. Solving the long-term adherence and tolerability bottleneck via an oral maintenance pill is the holy grail for the space. Phase 3 Oral Initiation (Q4 2026): VKTX plans to initiate pivotal Phase 3 trials for their oral tablet in Q4, validating their stunning Phase 2 oral data (12.2% weight loss in just 13 weeks) and locking in their competitive timeline. The Capitalization & M&A: VKTX is exceptionally well-capitalized with roughly $600M+ in cash. While they filed an ATM to fund their massive ongoing Phase 3 subcutaneous trials (VANQUISH 1 & 2), the sheer size of the TAM and the constant hum of buyout speculation give it explosive upward mobility on any good data.
CTMX	CytomX Therapeutics	The Catalyst Torque: CTMX is a pure near-term catalyst play centered on a Q4 2026 (likely October) 40-patient dose-optimization update for Varseta-M, a first-in-class EpCAM ADC. Efficacy vs. Tolerability: Phase 1 data already proved the drug works, showing a 28% confirmed response rate in unselected late-line mCRC (compared to single-digit standard of care). However, high doses caused severe diarrhea. The October data must prove they have found the "Goldilocks" dose that maintains efficacy while resolving the tolerability limits. The Financial Floor: Trading around $4/share, the stock is heavily cushioned by ~$367M in pro forma cash (following a recent Regeneron payment), extending the runway deep into 2H 2028. The financing overhang is completely cleared into the data. The Platform Re-Rate: If the October data is clean, it not only locks in the H1 2027 registrational trial design but validates CytomX's entire "Probody" masking technology. Proving the platform works safely instantly makes them a high-value M&A target in an ADC-hungry market.
GLSI	Greenwich LifeSciences	The M&A Binary: The thesis has formally shifted from a clinical data hold to a near-term corporate acquisition or major partnership play. Management's changing language around the seriousness of suitor discussions points to an active M&A process. If a deal is struck, the asymmetry is massive — potentially a 3x to 7x return from current ~$16/share levels. The Lock-Up Signal: The timeline indicator has been driven by shifting lock-up periods for directors and early investors, with the latest extension anchoring insiders to January 2027. This signals the structural window in which management expects value to be unlocked. The Clinical Foundation: The underlying asset driving the buyout interest is GLSI-100, currently in the FLAMINGO-01 Phase 3 trial for breast cancer recurrence. The Phase 2b data at MD Anderson showed an 80%+ reduction in recurrences over 5 years. Insider conviction remains high, backed by significant and consistent CEO share purchases.
CABA	Cabaletta Bio, Inc.	The Forever Low: Cabaletta is developing rese-cel (CABA-201), a CD19 CAR-T for autoimmune disease, and the stock trades near the $2.90 level where a blue-chip institutional syndicate — Bain Capital Life Sciences, Adage, Cormorant, and Eli Lilly — just bought $150M worth in May 2026. Buying here means buying alongside sophisticated money and a major pharma at essentially the same price, at the low end of the 52-week range, in a company funded into mid-2027. The Mechanism Edge: Rese-cel doesn't just suppress the immune system — it depletes the autoreactive B-cell compartment and lets the body repopulate with naive B cells that don't carry the autoimmune memory. It's a one-time depletion-and-reset rather than a standing therapy. The early preconditioning-free data (RESET-PV) suggests the reset can happen without harsh chemo lymphodepletion, which would open a far larger addressable population. The Data: Across the RESET program (myositis, SLE, systemic sclerosis, MG), the pattern has been consistent — patients who would have met the registrational primary endpoint did, with durability holding and a manageable safety profile. In the myositis Phase 1/2, roughly 83% of patients would have met the registrational endpoint, with durability out to 1.5 years. RMAT designation is in place. The Catalyst Path: The near-term drivers are the preconditioning-free durability data and higher-dose data in 2H 2026, plus initiation of the SSc registrational program in Q4 2026. The defining binary is the RESET-Myositis DM/ASyS registrational topline in mid-2027, which enables a myositis BLA in 2H 2027 (with potential priority review voucher eligibility via the juvenile cohort). The Thesis: This is my highest-conviction "structural low" entry. If the mid-2027 registrational data lands, I see a path to a 4x from here over 12–15 months — with the 2H 2026 catalysts converting the story and the anticipatory run-up starting before the readout. The Risk: The company will likely need to raise before the mid-2027 data. Given the annual cadence and accelerating burn, expect a raise around late 2026 / Q1 2027 — ideally into strength, as the May round was. If the run-up hasn't started when they need cash, a raise into weakness would reprice the floor lower.
HELP	Helus Pharma (Cybin)	The Mispriced Coin: HELP is developing HLP003, a deuterated psilocin analog for major depressive disorder, and the market is pricing in failure — the stock trades near cash value with a Q4 2026 Phase 3 topline (APPROACH) directly ahead. That combination, market skepticism plus a near-term binary, is exactly the asymmetric setup I look for: if the data hits, the re-rate is violent precisely because expectations are on the floor. The Read-Through I Trust: The single biggest reason for conviction is DFTX. MindMed's EMERGE Phase 3 in MDD just hit cleanly in June 2026 — 8.1-point placebo-adjusted MADRS, durable through week 12 — clearing the exact risks the market fears for psychedelic depression trials (functional unblinding, high placebo response, Phase 2-to-3 translation). The class just proved it can work in a powered Phase 3, and I own the name that proved it. The Data & Design: HLP003's Phase 2 showed a large, durable effect — a ~23-point MADRS reduction sustained at 12 months off just two doses, with response and remission rates climbing toward 100% and 71% at the 12-month mark. The deuteration engineers a predictable ~4-hour experience, addressing the practical duration knock on the class. Breakthrough Therapy Designation is in place, signaling the FDA sees substantial improvement over available therapy. The Catalyst Path: APPROACH Phase 3 topline is expected Q4 2026, with an FDA alignment goal on the approvable development program by year-end, and the complementary EMBRACE Phase 3 running in parallel to build the filing package. The Thesis: A high-probability Phase 3 (by my read, better than the market's implied odds) in a space I understand cold from DFTX, at a price that assumes it fails. If it hits, I see a path to roughly a 3x from here as the market re-rates from failure-priced to approvable-asset. The Risk: This is a single-asset binary — a miss on unblinding-adjusted numbers would be severe, and it's correlated to my DFTX psychedelic exposure, so a class-wide setback hits both together. Sized as a high-conviction bet I can absorb being wrong on, not as a settled outcome.
VLTLF	LibertyStream Infrastructure	From Concept to Producer: LibertyStream (formerly Volt Lithium) has officially transitioned from a speculative technology play to an active producer, successfully delivering their first tonne of finished lithium carbonate. They are now actively producing onsite with their partner, Select, effectively proving the commercial viability of extracting lithium from oil field brine. The Cost & Scale Advantage: While nearest competitors require massive capital injections (~$1.5B) and years of infrastructure layout to build a prototype, VLTLF's modular, highly capital-efficient model allows them to produce and scale rapidly from a tiny fraction of the cost. Strategic Domestic Supply: By turning oil field waste into a high-value commodity, they create an attractive secondary income stream for operators while serving as a highly secure, domestic supply of lithium for the US battery pipeline. Near-Term Catalysts: With production successfully de-risked, focus shifts to upcoming off-take agreements, additional JV announcements with major oil producers, the recently signed $95M non-dilutive project-financing term sheet, the 1,000-tonne facility commissioning targeted for late 2026, and the planned uplisting to the NASDAQ.
IMMX	Immix Biopharma Inc.	Market Monopoly: $IMMX is on track to deliver the first FDA-approved CAR-T for relapsed/refractory AL Amyloidosis—a "blue ocean" market with no current approved therapies and a potential $3B+ opportunity. Best-in-Class Efficacy: Recent Phase 2 data (ASH 2025) showed a 75% Complete Response (CR) rate, which is projected to reach 95% based on current bone marrow markers. This dwarfs the <10% response rates of current salvage therapies. The "Outpatient" Advantage: Unlike existing CAR-Ts that require intensive hospital stays, $IMMX's lead asset (NXC-201) has shown zero neurotoxicity and ultra-short (1-day) side effects. This allows for outpatient administration, making it cheaper for insurers and more accessible to the 95% of hospitals that can't currently handle "toxic" cell therapies. Near-Term Catalyst: The 40-patient BLA-enabling NEXICART-2 topline is expected September 2026, with a BLA submission to follow in 2H 2026. With a cash runway into 2027 and a clear regulatory path (RMAT designation), the approval is the primary value-unlock. Autoimmune Optionality: If the safety profile holds, NXC-201 is the perfect candidate to pivot into massive markets like Lupus or Myasthenia Gravis, where safety is the #1 barrier to entry.
CNVIF	Conavi Medical Corp.	CNVIF is a "disruptive med-tech" play on the only imaging system capable of combining the two gold standards of coronary diagnostics into a single device. The "Hybrid" Monopoly: Conavi's Novasight Hybrid System is the first and only platform to combine IVUS (ultrasound) and OCT (optical imaging) on a single catheter. This gives cardiologists a "super-view" of arteries that neither technology can provide alone. Imminent FDA Catalyst: In September 2025, the company submitted its next-generation system for FDA 510(k) clearance. A formal U.S. commercial launch is anticipated for 2H 2026, which serves as the primary near-term price driver. Guideline Tailwinds: Global medical guidelines (ACC/AHA/ESC) recently upgraded intravascular imaging to a Class 1A recommendation (the highest level). This mandate is forcing hospitals to adopt new imaging tech, creating a massive organic growth wave for $CNVIF. Freshly Capitalized: Following a $20M institutional raise in 2025 and an ongoing January 2026 public offering, the company has significantly de-risked its balance sheet to fund the upcoming U.S. sales force and manufacturing scale-up. Rapid Revenue Growth: Revenue grew from $2.2M to $9.1M in the last fiscal year (+300%). Analysts project revenue to continue growing at over 50% annually as the U.S. launch commences. UPDATE: Company announced FDA clearance as expected! I believe this is an excellent buy out candidate now. Most likely between now and end of 2026 at the latest.
LUCD	Lucid Diagnostics	The investment thesis for Lucid Diagnostics (LUCD) in 2026 centers on its transition from a clinical-stage diagnostic company to a commercially scalable oncology platform, primarily through its EsoGuard DNA test for the early detection of esophageal precancer. The bull case is anchored by recent major commercial wins, including a January 2026 U.S. Department of Veterans Affairs (VA) contract that grants access to nine million veterans, and a late-2025 unanimous expert consensus from the MolDx Contractor Advisory Committee supporting Medicare coverage. These catalysts address the company's historical "reimbursement gap," where high test volumes were previously unmatched by cash collections. With a strengthened balance sheet following a late-2025 public offering—extending the cash runway through late 2026—the thesis hinges on Lucid's ability to convert its $35 million+ revenue backlog into realized cash and scale toward an estimated break-even point of 6,000 tests per quarter. While the stock remains a high-risk, micro-cap play with significant cash burn, the imminent finalization of a national Medicare Local Coverage Determination (LCD) represents a binary "inflection point" that could re-rate the company from a speculative venture to a high-growth medical technology leader.
TSHA NGNE	Taysha Gene Therapies Neurogene Inc.	Why I Own Both: TSHA and NGNE are the only two pure-play gene therapy companies in Rett Syndrome, a devastating neurodevelopmental disorder with an enormous commercial vacuum. It's a clean two-horse race with no credible third gene therapy anywhere near registrational stage, and the approved Rett drug (trofinetide) is symptomatic and complementary rather than competitive. My conviction is high that Rett gene therapy works; it's lower on which of the two wins the head-to-head. Owning both matches my position to my conviction: the one variable I can't handicap well — which comparable program pulls ahead — stops being an existential risk to my book and becomes an internal reallocation. TSHA (TSHA-102): REVEAL Part A 12-month data in June 2026 confirmed the 100% response rate is holding and deepening (milestone gains up +94% from the 6-month mark). Pivotal dosing is complete (overenrolled to N=17), and the 6-month pivotal interim is expected 1H 2027, with a BLA to follow mid-2027. TSHA's intrathecal (lumbar) delivery is administered by a neurologist rather than a neurosurgeon, which is the more scalable commercial model. Well capitalized after its June 2026 raise. NGNE (NGN-401): Long-term Phase 1/2 data showed durable, multidomain gains, with no HLH at the 1E15 dose across all treated participants — the safety concern clustered at the abandoned high dose. Embolden registrational dosing is complete (n=25, overenrolled), with a 12-month primary endpoint and topline expected 2H 2027. NGNE also carries a second program (NGN-101 for CLN5 Batten disease) and runway into 2029. Its small share count (~20M shares) means it moves fast in both directions. The Sequencing: TSHA reads out registrational data first, creating a window where TSHA-specific news moves TSHA while NGNE has nothing new. NGNE's readout is its own event later in 2027. If both read out clean, I expect a "two validated winners" re-rating of the whole space. If one is weak, the other captures the value its rival vacates — which is exactly the scenario owning both protects against. The Holding Plan: I'm holding both through both 2027 registrational readouts and beyond, rather than trading the individual catalysts. The Risk: The pairing hedges which company wins, not whether the space works. A sector-wide gene therapy scare — a safety event at an unrelated AAV program, or an FDA shift on accelerated approval — would hit both together. These are still small datasets where a single new serious adverse event can move either stock sharply, especially NGNE given its thin float.
OCUL	Ocular Therapeutix, Inc.	The Superiority Win: Ocular is developing AXPAXLI, a sustained-release axitinib (TKI) intravitreal implant for wet AMD. In February 2026, its SOL-1 Phase 3 became the first wet AMD trial ever to show superiority of a novel agent over an approved anti-VEGF. Conducted under an FDA Special Protocol Assessment, it met its primary endpoint at Week 36 (p=0.0006): 74.1% of AXPAXLI patients maintained vision versus 55.8% on a single dose of aflibercept (2 mg), and roughly two-thirds of AXPAXLI patients went a full year without rescue after a single dose. The Accelerated Path: After a positive Type C meeting, the FDA confirmed Ocular can file its NDA on SOL-1 efficacy plus interim SOL-R safety, without waiting on SOL-R efficacy. The NDA is planned for Q4 2026 via the 505(b)(2) pathway (axitinib is an already-approved molecule), which puts a potential first approval around late 2027 and could make AXPAXLI the first TKI to reach the wet AMD market. The Durability Edge: The retina market is dominated by injections every one to four months. AXPAXLI is aiming at six months or longer from a single implant, with a superiority claim over an anti-VEGF that no competitor has. Durability is the attribute physicians and patients value most, and it's where AXPAXLI's data is strongest. The Upside Optionality: Ocular amended SOL-R to stay masked through Week 96 and added a key secondary endpoint testing superiority against high-dose aflibercept (8 mg), plus endpoints on preventing fibrosis and atrophy. Topline is expected Q1 2028. A win there would position AXPAXLI as best-in-disease rather than just best-in-durability. The HELIOS-3 Phase 3 in diabetic retinopathy adds a second large indication. The Competitive Read: Kodiak's Zenkuda (DAYBREAK) data hit OCUL hard, but I see the drop as an overreaction. The trials aren't comparable: SOL-1 was a superiority trial on a single dose, while DAYBREAK was a non-inferiority trial with individualized redosing. Zenkuda's population is broader and closer to real-world practice, but AXPAXLI's durability and superiority result remain unmatched. The wet AMD market is large enough for more than one winner. Kodiak's full data at AAO in October will sharpen the comparison. The Balance Sheet: Ocular entered 2026 with roughly $737M in cash and runway into 2028, funding the company through the NDA review and launch preparation. The Risk: The NDA rests on a single pivotal trial, and SOL-1 enrolled selected strong responders, so the FDA's review and the eventual label (especially the durability interval it allows) are the key swing factors. The launch will be more crowded than it looked a year ago, and short interest is elevated, which can make the stock volatile around competitor news.
KYTX	Kyverna Therapeutics, Inc.	KYTX is a "first-mover" play on the transition of CAR-T therapy from oncology into massive autoimmune markets, specifically targeting neuroimmunology. Pivotal Success in SPS: Kyverna reported positive Phase 2 registrational data for its lead asset, miv-cel (KYV-101), in Stiff Person Syndrome (SPS). The trial met its primary endpoint with a 46% median improvement in mobility, significantly exceeding the 20% clinical benchmark. The "Safety Shield": Miv-cel is designed to be safer than oncology CAR-Ts. Across all indications (SPS, MG, Lupus), it has shown zero high-grade ICANS and manageable CRS — essential for treating non-cancer patients. Balance Sheet Cushion: Roughly half the market cap is cash (runway into 2028), which provides real downside protection while awaiting the regulatory catalysts. The Catalyst Path: Longer-term Phase 2 gMG follow-up data (1-year+) landed as a hit in September 2026. The rolling SPS BLA is guided to complete in Q4 2026, with FDA acceptance and a PDUFA date expected around January–February 2027 — historically the first re-rate trigger for names like this. A potential approval around mid-2027 would make miv-cel the first-ever FDA-approved autoimmune CAR-T and is the biggest single value inflection. The gMG Phase 3 (KYSA-6) primary readout follows in March 2028. The Risk: An equity raise is likely in H1 2027 to fund the commercial launch, ideally timed into acceptance or approval strength.

Watchlist: Former Holdings

Positions previously held — theses retained for potential re-entry as catalysts approach

Ticker	Company	Thesis (Retained for Re-Entry)
HROW	Harrow Inc.	The Underappreciation: Harrow is the fastest-growing ophthalmology company most investors haven't yet priced as such. The infrastructure, leadership, and operational execution are already in place to deliver outsized growth. The Growth Window: Quarter-over-quarter growth should outpace what the market is currently pricing in, and that growth rate should last for the next 6-8 quarters and beyond. What the Market Misses: The current price reflects a steady specialty ophthalmics company. The reality is a commercial inflection underway with multiple simultaneous catalysts driving toward management's $250M quarterly revenue target by end of 2027 — roughly a 3x expansion from where revenue runs today. Re-Entry Signal: The January 2027 OPUVIZ (Eylea biosimilar) launch and progression toward the Q4 2027 revenue milestone are the markers worth watching for a re-entry.
VSTM	Verastem Oncology	VSTM is a high-conviction targeted oncology thesis centered on breaking down difficult-to-treat RAS-pathway driven tumors using their lead combinations. Near-term validation begins with the Phase 1 expansion data for VS-7375, which stands to trigger the stock's first major fundamental re-rating by validating its utility in the high-value KRAS G12D mutation space. The broader clinical thesis is anchored by the RAMP 205 expansion data in pancreatic cancer (PDAC) alongside formal FDA registrational engagement. With clear visibility toward entering registrational Phase 2 trials by Q1 2027 and a definitive Phase 3 RAMP 301 clinical readout slated for mid-2027, Verastem presents a highly organized clinical sequence targeting heavily underserved solid tumor markets. Re-Entry Signal: The mid-2027 RAMP 301 Phase 3 topline is the key binary worth watching. The June 2026 NSCLC Fast Track and TARGET-D 101 data updates are interim signals on the way there.
QURE	uniQure N.V.	The Original Thesis: uniQure is developing AMT-130, a one-time gene therapy for Huntington's disease — a devastating, uniformly fatal neurodegenerative disorder with zero approved disease-modifying treatments. In June 2026, the FDA agreed that the 3-year Phase I/II data could serve as the primary basis for a BLA under accelerated approval, reversing its March 2026 position. The BLA and a parallel UK MAA were submitted in September 2026. Why I Exited: I sold after the 4-year data. My read is that the control database couldn't be relied upon for this year's comparison — and if that's true, it casts doubt on the data points the FDA already has in hand for the BLA. That made the worst-case scenario meaningfully more likely: no approval, and a full trial required before the FDA would reconsider a new BLA. Combined with the earlier surprise of much heavier confirmatory-trial requirements, the risk/reward no longer justified holding. Pipeline Optionality: Beyond Huntington's, uniQure is advancing AMT-260 for refractory mesial temporal lobe epilepsy (early Cohort 1 data positive) and AMT-191 for Fabry disease. The balance sheet is strong following the June 2026 raise. Re-Entry Signal: The FDA's filing decision on the BLA (expected by ~November 2026) and the outcome of any advisory committee. Clear evidence that the FDA accepts the existing data package without demanding a new trial would reopen the approval asymmetry.
MDNAF	Medicenna Therapeutics Inc.	The IL-2 Space Background: Pharma poured many billions into IL-2 because of the promise of stimulating the body's own natural immune response to fight cancer, but toxicity levels were always too high. It has taken many years for the IL-2 space to re-emerge thanks to engineered versions like MDNA11. MDNA11 Mechanism Edge: MDNA11 selectively activates the "gas pedal" of the immune system (CD8+/NK cells) while removing the "brake" (Tregs) and the "danger" (Vascular Leak Syndrome). It's in Phase 1/2 across multiple cancer types, both as a monotherapy and in combination with Keytruda, with excellent early monotherapy results and promising combination data. The Buyout Case: Recent deals and acquisitions in the engineered IL-2 space are in the $1-2B range, and MDNA11 is so far proving best-in-class against the rest of the field. Why I Exited: The science still looks good, but this is now a funding issue. The company is dangerously low on cash, and without a partnership or buyout, further dilution is likely to compress the per-share value of any eventual deal. Re-Entry Signal: A partnership, buyout, or financing that resolves the cash runway without crushing existing shareholders. I may re-enter depending on how the funding question is answered.
DFTX	Definium Therapeutics (formerly MindMed)	The Original Thesis: DFTX was a high-conviction binary play in neuropsychiatric medicine built on DT120 (formerly MM120) for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The thesis played out: the EMERGE Phase 3 in MDD hit cleanly in June 2026 (8.1-point placebo-adjusted MADRS improvement, durable through week 12), and both GAD Phase 3s — Voyage (August 2026) and Panorama (September 2026) — also hit. DFTX is positioned as a first-mover in a massive, largely unaddressed market, with an NDA submission planned for Q1 2027. Why I Exited: With all three Phase 3 readouts positive, the clinical binaries that drove my thesis are behind it. DFTX is now a regulatory story — NDA submission, FDA review, label, and any REMS requirements — which is a different risk profile from the catalyst setups I focus on. Re-Entry Signal: I may re-enter depending on how the regulatory path develops: the Q1 2027 NDA submission, FDA acceptance, and clarity on label and REMS requirements ahead of a potential approval.
IREN	IREN Limited (formerly Iris Energy)	The Diversification Pivot: IREN was my deliberate move outside the biotech binary — a cash-generating AI-infrastructure operator rather than another clinical coin-flip, with growth driven by contracts and operational execution instead of a single FDA readout. From Bitcoin Miner to AI Landlord: Rebranded from Iris Energy in late 2024, IREN redeployed its power, land, and construction expertise out of bitcoin mining and into purpose-built, liquid-cooled AI / HPC data centers. It operates ~810MW of data centers and controls ~2,900MW of grid-connected power across 2,000+ acres — scarce, hard-to-replicate assets at a moment when power is the binding constraint on the AI buildout. The Contract Backlog: IREN has signed a $9.7B five-year AI cloud agreement with Microsoft, a $3.4B contract with Nvidia, and a ~$2.8B multi-customer wave in which customers prepaid roughly 45% of the GPU capex. Management is targeting an annualized revenue run-rate above $4B exiting 2026. The Power Pipeline: Sweetwater 1 (1.4GW) energized on schedule in April 2026, with Sweetwater 2 (600MW) targeted for late 2027 to complete a 2GW Texas hub, on top of a multi-gigawatt development pipeline. The Risk: Heavy capital intensity, dependence on the AI-capex cycle continuing, ERCOT interconnection and construction-timing execution, and residual bitcoin-price exposure through the legacy mining fleet. Re-Entry Signal: The thesis is intact. I may re-enter on a dip.

Data current for active portfolio positions Updated October 2026